Research Library / Neurocognitive / PE-22-28
Neurocognitive researchPE-22-28 (Mini-spadin)
PE 22-28 · PE22-28 · PE2228 · Mini-spadin · GVSWGLR
A seven-amino-acid spadin fragment studied in cells and mouse behavioral models relevant to mood and neuroplasticity. The listed community example (published community-guide range — unvalidated) describes 100–200 mcg per administration, once daily, via subcutaneous — anecdotal, not studied human dosing; this is not a validated dosing recommendation. An illustrative 5 mg vial at an assumed 2.5 mL final volume yields 2 mg/mL; diluent compatibility remains product-specific. For research and education only, not personal medical guidance.
Quick Reference
- Example vial
- 5mg
- Assumed final volume
- 2.5mL · not an amount to add
- Concentration
- 2mg/mL · conditional arithmetic
- One U-100 marking
- 20mcg in 0.01 mL
Hypothetical vial math does not reproduce a study formulation or verify a diluent, sterility or storage period.
Research schedules
PE-22-28: 3 mcg/kg intraperitoneally in mouse experiments, including four-day sub-chronic treatment; not a human or subcutaneous regimen
Mouse behavioral models and cultured cells; not human participantsFrontiers in Pharmacology, 2017No established human dose, route, frequency, titration or treatment duration identified in this review
Search includes PE-22-28 and spadin; a registry search is not proof that every possible trial name was capturedClinicalTrials.gov search — not a dosing studyReported schedule context
- Range
- 100–200 mcg/day in a secondary community guide; not validated
- Frequency
- Once daily reported
- Route
- Subcutaneous reports; no established human route
- Reported half-life
- Not established in humans; mouse action duration is not a human half-life
- Reported cycle
- 4–8 weeks reported by community guides; no validated cycle or break
Commercial/community guides report variable amounts and may repeat one another. The displayed range is a report, not a safe maximum, recommended dose or evidence of efficacy. No evidence-based loading phase or escalation is established. The linked community source is listed with the preparation references, separate from the primary animal study.
Cross-reference reviewed November 2, 2026. Half-life and cycles retain this source context.| Context / phase | Amount | Schedule total | Frequency | Timing | Route | Evidence |
|---|---|---|---|---|---|---|
| Published community-guide range — unvalidated | 100–200 mcg | 100–200 mcg/day | Once daily | Morning reported; not clinically validated | Subcutaneous — anecdotal, not studied human dosing | Community-reported |
Repeated community reports do not establish identity, safety, effectiveness or an appropriate exposure. Component schedules do not validate a same-vial blend.
Vial calculator
Linked to Quick Reference and compatible supply calculations.
Read the needle-side edge of the black stopper. Liquid tint is illustrative.
Scale illustration · one U-100 marking = 0.01 mL.
Arithmetic yield at this example amount
50 example portions per vial
50 full amounts; 0 mg remaining. Yield is not a storage or reuse period.
See the calculation
Concentration = vial content ÷ final volume. Volume = example amount ÷ concentration. U-100 markings = mL × 100.
Original example & formulation context
100 mcg arithmetic example — not a validated human dose · 2 mg/mL · 0.05 mL · 5 units
Hypothetical vial-content arithmetic only: 5 mg at a 2.5 mL final volume gives 2 mg/mL; 100 mcg is 0.05 mL (5 U-100 units), and 200 mcg is 0.10 mL (10 units). This is not an instruction to add 2.5 mL BAC water. Product-specific solubility, actual final volume, container capacity and preparation method must be verified. No nasal-spray preparation or validated injectable formulation is inferred. Supplier solubility figures differ: Tocris lists water solubility to 2 mg/mL, while MedChemExpress lists 21.7 mg/mL with laboratory processing. These are product-specific reagent specifications, not validated BAC-water or human injection protocols. The calculation assumes the stated final solution volume, which may differ from liquid added. It does not verify dissolution, solvent compatibility, sterility, chemical stability or storage. See the source-linked preparation notes below.
Supplies & vial yield
5 mg (hypothetical) · 2.5 mL assumed final solution volume; diluent product-specific · Published community-guide range — unvalidated
Vial counts and final solution totals below use the selected 5 mg example at 2.5 mL. The original schedule totals stay unchanged.
Schedule phases used for planning
| Phase | Amount | Frequency | Weekly total |
|---|---|---|---|
| Selected planning schedule | 100–200 mcg | Once daily | 0.7–1.4 mg/week |
Peptide vials
| Horizon | Total | Vials* |
|---|---|---|
| 4 weeks | 2.8–5.6 mg | 1–2 × 5 mg |
| 8 weeks | 5.6–11.2 mg | 2–3 × 5 mg |
| 12 weeks | 8.4–16.8 mg | 2–4 × 5 mg |
Liquid planning
| Horizon | Final volume* | Diluent supplies |
|---|---|---|
| 4 weeks | 2.5–5 mL | Not established |
| 8 weeks | 5–7.5 mL | Not established |
| 12 weeks | 5–10 mL | Not established |
Administration count
| Horizon | Administrations |
|---|---|
| 4 weeks | 28 |
| 8 weeks | 56 |
| 12 weeks | 84 |
Original schedule counts. Check the calculated volume against syringe capacity; no split-dose technique is assigned.
Original vial-life context
4 weeks: 25–50 administrations
8 weeks: 25–50 administrations
12 weeks: 25–50 administrations
Applies to the original planning basis above; not a product stability period.
Ranges reflect the low and high ends of the selected displayed schedule (community-reported). Vials are rounded up; one new U-100 syringe is counted per subcutaneous administration. Liquid totals are conditional final solution volumes, not verified quantities to add. Diluent bottle counts are withheld pending product-specific preparation instructions. Arithmetic does not establish storage or reuse periods.
*Conditional mass and final-volume arithmetic. No stability, sterility, safe reuse period or verified diluent quantity is established. Cleansing materials, sterile supplies, labels and sharps disposal follow the actual research procedure.
Protocol overview & research context
- Identity
- PE-22-28 · PE 22-28 · PE22-28 · PE2228 · Mini-spadin · GVSWGLR
- Evidence / status
- Preclinical. Not FDA approved; no established human clinical protocol
- Clinical route, frequency & duration
Preclinical spadin-analog study — not a human protocol: PE-22-28: 3 mcg/kg intraperitoneally in mouse experiments, including four-day sub-chronic treatment; not a human or subcutaneous regimen
Human-trial evidence review · November 2, 2026: No established human dose, route, frequency, titration or treatment duration identified in this review
- Community purpose
- Mood, stress resilience and neuroplasticity discussions. These community claims are not demonstrated human benefits or a depression-treatment recommendation.
- Reported timing / route
- Once daily reported · Subcutaneous reports; no established human route. Schedule-specific timing remains in the Community tab.
- Reported half-life
- Not established in humans; mouse action duration is not a human half-life · community-reference context, not a shelf life.
- Reported cycle
- 4–8 weeks reported by community guides; no validated cycle or break. Planning horizons do not establish a validated cycle.
Loading, titration and maintenance
A separate loading phase is not identified in this library entry. Titration, maintenance and stopping rules depend on the specific product or study; a listed range is not automatically an escalation plan.
Reconstitution & formulation
Supplier solubility figures differ: Tocris lists water solubility to 2 mg/mL, while MedChemExpress lists 21.7 mg/mL with laboratory processing. These are product-specific reagent specifications, not validated BAC-water or human injection protocols.
Other vehicles and approaches discussed
Water, organic-solvent stocks and community BAC-water examples describe different materials and laboratory or anecdotal contexts. None establishes a universal injectable diluent, concentration, mixed-solvent ratio or storage period.
- Evidence context
- No new alternate-solvent requirement established
- Cloudiness / gel signal
- Formulation-specific solubility; gelling incidence and injectable stability not established
- Product details to verify
- Verify identity, sequence, salt form, actual content, excipients, intended method, final concentration, container capacity and lot-specific preparation instructions.
Laboratory solubility does not establish sterility, human-route suitability, chemical stability or a beyond-use period. Organic laboratory solvents are not injection instructions. Do not use cloudy, precipitated or gelled material; no salvage method is provided.
Preparation references reviewed November 2, 2026.
Preparation documentation checklist
- Confirm identity, nominal content, salt form, buffer and excipients.
- Verify the actual product's diluent, amount to add and intended method.
- Calculate concentration from final solution volume, and cross-check units.
- Record lot, concentration, diluent, preparation date, storage and discard instructions.
This checklist does not replace a validated preparation procedure.
Storage, clarity & stability
- Unopened product
- Follow its documented temperature, light protection, shipping and expiration requirements.
- Prepared material
- Chemical stability and microbial safety are formulation-specific. A diluent bottle's discard period does not establish the compound's storage period.
- Visible-change context
- Formulation-specific solubility; gelling incidence and injectable stability not established
Unexpected cloudiness, particles or gel
For a product intended to form a clear solution, do not use or attempt to salvage unexpected persistent clouding, strings, precipitate, thickening or gel. Labeled suspensions, including some triptorelin depots, have their own expected appearance and instructions.
Why vial yield does not establish shelf life
Arithmetic portions assume the material remains usable. Chemical degradation, contamination, handling losses and required discard limits may reduce practical yield. Freezing, warming, acidifying or further diluting cannot be assumed to restore quality.
No universal refrigerated, room-temperature or 90-day beyond-use period is assigned by the calculator.
How it works
Shortened spadin-derived peptide investigated for TREK-1 potassium-channel inhibition
A seven-amino-acid spadin fragment studied in cells and mouse behavioral models relevant to mood and neuroplasticity. Animal findings do not establish antidepressant efficacy in people.
Community-reported purpose
Mood, stress resilience and neuroplasticity discussions. These community claims are not demonstrated human benefits or a depression-treatment recommendation.
Reported purposes and marketing use-cases are not an approved indication or proof of efficacy.
Clinical findings & study landscape
Preclinical spadin-analog study — not a human protocol
Protocol: PE-22-28: 3 mcg/kg intraperitoneally in mouse experiments, including four-day sub-chronic treatment; not a human or subcutaneous regimen
Population: Mouse behavioral models and cultured cells; not human participants
Read the cited evidenceHuman-trial evidence review · November 2, 2026
Protocol: No established human dose, route, frequency, titration or treatment duration identified in this review
Population: Search includes PE-22-28 and spadin; a registry search is not proof that every possible trial name was captured
Read the cited evidenceFindings apply to the tested product, population and methods. A registry listing, mechanistic study or evidence-landscape link is not itself proof of efficacy or validation of an online vial.
Safety, evidence limits & regulatory status
Compound-specific safety context
Human safety, interactions, bioavailability and injectable pharmacokinetics are not established. Mouse behavioral effects do not demonstrate treatment of depression in people. The reported prolonged mouse action is not a measured human half-life. Community schedules and research-vial preparations are unvalidated.
Development and regulatory status
Not FDA approved; no established human clinical protocol
Approval of a named product does not extend to every vial, formulation, route, blend or indication carrying a related name.
What this guide cannot establish
The library does not authenticate a product or determine a personal starting dose, missed-dose rule, restart regimen, interaction plan or combination protocol. Study schedules, community reports and vial calculations retain separate evidence labels.
Frequently asked questions
What is PE-22-28?
A seven-amino-acid spadin fragment studied in cells and mouse behavioral models relevant to mood and neuroplasticity. Animal findings do not establish antidepressant efficacy in people.
Shortened spadin-derived peptide investigated for TREK-1 potassium-channel inhibition
Does vial strength mean the amount per administration?
No. A vial's label states nominal contents. The amount used in a study belongs to its assigned product and protocol. Changing vial strength changes concentration and yield, not the study's assigned amount.
Why does changing final volume change the U-100 value?
A larger final volume reduces concentration for the same mass. U-100 markings are volume measurements: one marking equals 0.01 mL. They are not biological international units of a peptide.
What happens when a calculation exceeds one syringe or vial?
Available mass and syringe capacity are separate limits. The calculator flags a result above 1 mL; it does not provide a splitting or combining technique.
Is there a loading phase or standard cycle?
A separate loading phase is not identified in this entry. Do not infer one from a range of reported amounts.
4–8 weeks reported by community guides; no validated cycle or break
Which diluent and storage period should this material use?
Supplier solubility figures differ: Tocris lists water solubility to 2 mg/mL, while MedChemExpress lists 21.7 mg/mL with laboratory processing. These are product-specific reagent specifications, not validated BAC-water or human injection protocols.
Calculation examples do not establish solvent compatibility, sterility or shelf life.
Where do I track or calculate a multi-phase schedule?
The Free Planner supports saved research examples and multi-phase planning. This guide's calculator is local to the page and does not save a protocol automatically.
Open Free PlannerReferences & evidence trail
- Clinical / regulatory / evidence landscapeFrontiers in Pharmacology, 2017: Preclinical spadin-analog study — not a human protocol
- Clinical / regulatory / evidence landscapeClinicalTrials.gov search — not a dosing study: Human-trial evidence review · November 2, 2026
- Laboratory supplier — product-specificTocris PE 22-28 reagent specifications
- Laboratory supplier — product-specificMedChemExpress PE 22-28 solubility specifications
- Commercial/community report — unvalidatedPE-22-28 community-guide schedule — not clinical evidence
Clinical sources remain attached to their studies; laboratory and community formulation sources retain their own limits. Preparation review dates do not imply that every clinical study was newly reviewed today.
Independent educational research reference. Not medical advice or an individualized dosing recommendation.